A Phase 2 interventional study of bimatoprost ophthalmic solution 0.005% and bimatoprost ophthalmic solution 0.015% in Eyelash Hypotrichosis, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2011-12-09.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hypotrichosis by AbbVie — none open to participants now, none under way, none of them phase 3. Hypotrichosis · AbbVie.
Among the 11 studies in Hypotrichosis by AbbVie, this one is one of 2 that started in 2010, is the only one in phase 2, and was the 3rd registered.
24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.
Browse Hypotrichosis studies →None of the 11 studies in Hypotrichosis by AbbVie is open now. The open studies under Hypotrichosis, anywhere →
Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 30 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2010.
This study's enrollment of 104 is above the median of 56 across 22 interventional studies indexed under Hypotrichosis.
Median enrollment 104 across the 9 interventional studies, 1,142 across the 2 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Hypotrichosis by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
bimatoprost ophthalmic sterile solution 0.005%
Drug: bimatoprost ophthalmic solution 0.005%
bimatoprost ophthalmic sterile solution 0.015%
Drug: bimatoprost ophthalmic solution 0.015%
bimatoprost ophthalmic solution 0.03%
Drug: bimatoprost ophthalmic solution 0.03%
One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
Also known as: LATISSE®
Change From Baseline in Eyelash Length at Month 3
Change from Baseline at Month 3 in eyelash length, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.
Time frame: Baseline, Month 3
Change From Baseline in Upper Eyelash Thickness at Month 3
Change from baseline in upper eyelash thickness/fullness at Month 3 was measured within 3 preset areas. Eyelash thickness/fullness was assessed across both eyes as an average of the 3 preset areas measured in millimeters squared (mm\^2). Changes from baseline to Month 3 represented by positive values indicated increased eyelash thickness, and changes from baseline represented by negative values indicated thinner eyelash thickness.
Time frame: Baseline, Month 3
Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3
Change from baseline in upper eyelash darkness at Month 3 was determined by lash intensity within the spline (a narrow area approximately 5 pixels wide that bisects the area of interest). Upper eyelash darkness was measured in both eyes and averaged for analysis. Colors ranged from black=0 to white=255. Lower numbers on this continuum indicated darker colors. Therefore, a change from baseline to Month 3 represented by a negative value indicated increased eyelash darkening.
Time frame: Baseline, Month 3
Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3
Percentage of subjects with a clinical response in overall eyelash prominence at Month 3 was measured using a 4-point GEA scale with the aid of the photonumeric guide. The scale ranges from 1 (minimal = worst) prominence to 4 (very marked = best)prominence. Eyelash prominence was assessed and graded by the investigator over both eyes. A clinical response was defined as at least a 1-grade increase in GEA score from baseline to Month 3.
Time frame: Month 3
Change From Baseline in Overall Eyelash Satisfaction at Month 3
Change from baseline at Month 3 in question 3 "overall, how satisfied are you with your eyelashes?" Responses ranged from 1 (very unsatisfied = worst) to 5 (very satisfied = best). Individual responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.
Time frame: Baseline, Month 3
Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3
Change from baseline in the CAP domain at Month 3 included responses to questions 7, 8, and 9. Responses to each question ranged from 1 (very much disagree = worst) to 5 (very much agree = best) with the minimum sum of the scores for the domain equal to 3 and the maximum sum of the scores for the domain equal to 15. Domain responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.
Time frame: Baseline, Month 3
Treatment Satisfaction Questionnaire Score at Month 3
The Treatment Satisfaction Questionnaire at Month 3 consisted of 2 questions that collected information regarding subject satisfaction with the treatment overall. The questions assessed the likelihood that the subject would use the product, as well as the likelihood that the subject would recommend the product to family and/or friends, if it were available. The score was based on the responses to each question. Questions were answered on a 5-point scale ranging from 1 (very unlikely = worst) to 5 (very likely = best).
Time frame: Month 3
| Milestone | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Started | 36 | 34 | 34 |
| Completed | 34 | 32 | 32 |
| Not completed | 2 | 2 | 2 |
Change from Baseline at Month 3 in eyelash length, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.
| millimeters (mm) | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Baseline | 5.65 ± 0.763 | 5.68 ± 0.613 | 5.95 ± 0.744 |
| Change from Baseline at Month 3 | 0.74 ± 0.684 | 0.92 ± 0.668 | 1.36 ± 0.944 |
Change from baseline in upper eyelash thickness/fullness at Month 3 was measured within 3 preset areas. Eyelash thickness/fullness was assessed across both eyes as an average of the 3 preset areas measured in millimeters squared (mm\^2). Changes from baseline to Month 3 represented by positive values indicated increased eyelash thickness, and changes from baseline represented by negative values indicated thinner eyelash thickness.
| Millimeters squared (mm^2) | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Baseline | 12.75 ± 5.502 | 14.67 ± 7.540 | 13.69 ± 6.753 |
| Change from Baseline at Month 3 | 4.50 ± 4.760 | 5.64 ± 5.238 | 8.48 ± 7.387 |
Change from baseline in upper eyelash darkness at Month 3 was determined by lash intensity within the spline (a narrow area approximately 5 pixels wide that bisects the area of interest). Upper eyelash darkness was measured in both eyes and averaged for analysis. Colors ranged from black=0 to white=255. Lower numbers on this continuum indicated darker colors. Therefore, a change from baseline to Month 3 represented by a negative value indicated increased eyelash darkening.
| Units on a Scale | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Baseline | 157.14 ± 22.814 | 154.41 ± 21.065 | 162.41 ± 17.321 |
| Change from Baseline at Month 3 | -18.75 ± 23.276 | -26.55 ± 22.505 | -29.61 ± 20.443 |
Percentage of subjects with a clinical response in overall eyelash prominence at Month 3 was measured using a 4-point GEA scale with the aid of the photonumeric guide. The scale ranges from 1 (minimal = worst) prominence to 4 (very marked = best)prominence. Eyelash prominence was assessed and graded by the investigator over both eyes. A clinical response was defined as at least a 1-grade increase in GEA score from baseline to Month 3.
| Percentage of Subjects | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3 | 52.8 | 79.4 | 85.3 |
Change from baseline at Month 3 in question 3 "overall, how satisfied are you with your eyelashes?" Responses ranged from 1 (very unsatisfied = worst) to 5 (very satisfied = best). Individual responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.
| Scores on a Scale | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Baseline | 1.47 ± 0.560 | 1.56 ± 0.613 | 1.71 ± 0.524 |
| Change from Baseline at Month 3 | 1.35 ± 1.323 | 2.25 ± 1.368 | 2.06 ± 0.840 |
Change from baseline in the CAP domain at Month 3 included responses to questions 7, 8, and 9. Responses to each question ranged from 1 (very much disagree = worst) to 5 (very much agree = best) with the minimum sum of the scores for the domain equal to 3 and the maximum sum of the scores for the domain equal to 15. Domain responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.
| Scores on a Scale | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Baseline | 4.33 ± 2.098 | 4.53 ± 1.830 | 4.94 ± 2.029 |
| Change from Baseline at Month 3 | 2.79 ± 3.198 | 4.72 ± 3.752 | 3.06 ± 2.526 |
The Treatment Satisfaction Questionnaire at Month 3 consisted of 2 questions that collected information regarding subject satisfaction with the treatment overall. The questions assessed the likelihood that the subject would use the product, as well as the likelihood that the subject would recommend the product to family and/or friends, if it were available. The score was based on the responses to each question. Questions were answered on a 5-point scale ranging from 1 (very unlikely = worst) to 5 (very likely = best).
| Scores on a Scale | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| If Avail, How Likely Would You Continue to Use It? | 4.1 ± 1.21 | 4.2 ± 1.14 | 4.1 ± 0.93 |
| If Avail, How Likely Would You Recommend It? | 4.1 ± 1.26 | 4.2 ± 1.07 | 4.4 ± 0.61 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimatoprost Ophthalmic Solution 0.005% | — | 0/36 (0%) | 0/36 (0%) |
| Bimatoprost Ophthalmic Solution 0.015% | — | 1/34 (2.9%) | 7/34 (20.6%) |
| Bimatoprost Ophthalmic Solution 0.03% | — | 0/34 (0%) | 2/34 (5.9%) |
| Event | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/36 | 1/34 | 0/34 |
| Event | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% |
|---|---|---|---|
| Eyelids PruritusEye disorders | 0/36 | 3/34 | 2/34 |
| Eyelid PainEye disorders | 0/36 | 2/34 | 0/34 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/36 | 2/34 | 0/34 |
| Age Continuous(years) | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% | Total |
|---|---|---|---|---|
| Mean | 46.9 (32 to 55) | 45.4 (33 to 55) | 46.7 (31 to 55) | 46.3 (31 to 55) |
| Sex: Female, Male(Participants) | Bimatoprost Ophthalmic Solution 0.005% | Bimatoprost Ophthalmic Solution 0.015% | Bimatoprost Ophthalmic Solution 0.03% | Total |
|---|---|---|---|---|
| Female | 36 | 34 | 34 | 104 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2010, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimatoprost Ophthalmic Solution